A Phase 1 study found that the new radioligand therapy [177Lu]Lu-D-Dan-Phe-PSMA is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC). The treatment was designed to stay in the body and tumors longer than current therapies such as Pluvicto, allowing it to deliver more radiation directly to cancer cells.
In the highest dose group (3.70 GBq), all patients had lower PSA levels after treatment, and about two-thirds achieved a partial tumor response. The disease control rate in this group was 100%.
The therapy was generally well tolerated, with no life-threatening side effects or dose-limiting toxicities reported. The most common side effects were mild anemia and low white blood cell counts.
Researchers concluded that the 3.70 GBq dose showed the best balance of safety and effectiveness and should be tested further in larger clinical trials.